BIIB · NASDAQ · STOCK
Biogen (BIIB) Stock Analysis
$218.16
52W $131.52 – $222.15
62/100
$32.03B
38.2
0.16
⚠
Buy rating, but near-term risk/reward is unfavorable
The long-term recommendation is based on the composite investment score. The near-term risk/reward is based on nearby support and resistance levels. These can differ when a strong company trades close to resistance with support further below.
Is BIIB Bullish or Bearish?
Bullish.
Innellis AI committee rates Biogen (BIIB) Buy with a composite score of 62/100
, based on 6 analysts with 67% agreement.
Last updated August 24, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +12.90 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -7.10 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The primary driver is news sentiment is positive (+0.40 across 10 articles, 14d). The main limiting factor is p/e of 37.2 is moderate-to-rich. The committee is constructive but not yet at full conviction.
Bull & Bear Case
Bull Case
- Price-to-book of 1.4x is a discount to asset value — Value
- 5 consecutive earnings beats -- consistent execution — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- News sentiment is positive (+0.40 across 10 articles, 14d) — News
Bear Case
- P/E of 37.2 is moderate-to-rich — Value
- ROE of only 4.5% -- cheap may mean cheap for a reason — Value
- EPS declining -46.0% YoY despite any revenue growth — Growth
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of August 24, 2026
Overall Committee Score
62/100
Agreement
67%
Analysts
6
Conviction
Moderate
Sector Rank
Top 24%
of 192 Healthcare peers
Value Analyst
neutral
55
/ 100 · High confidence
Fair value -- neither a bargain nor obviously overpriced
+ Price-to-book of 1.4x is a discount to asset value
− P/E of 37.2 is moderate-to-rich
Growth Analyst
neutral
44
/ 100 · High confidence
Moderate growth -- present but not remarkable
+ 5 consecutive earnings beats -- consistent execution
− EPS declining -46.0% YoY despite any revenue growth
Technical Analyst
bullish
68
/ 100 · High confidence
Price action is constructive -- trend and momentum agree
+ Price structure making higher highs and higher lows
Risk Analyst
bullish
70
/ 100 · Low confidence
Risk profile is manageable -- leverage, volatility, and event exposure all look contained
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
bullish
70
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.40 across 10 articles, 14d)
Portfolio Manager
neutral
45
/ 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 3069.37)
Investment Thesis Evolution
Committee score moved marginally from 62.1 to 62.1.
Comparing 2026-08-23 to 2026-08-24 (1 day apart).
Technical Analysis
RSI (14)
61.5
Neutral
MACD Histogram
0.978
Bullish Momentum
Trend Direction
Uptrend
Weekly: Sideways
Market Structure
Mixed
Support
$210.78
Resistance
$218.85
Bollinger %B
0.91
Inside Bands
Price vs Moving Averages
EMA 9
$212.97
Above
EMA 21
$209.45
Above
EMA 50
$204.87
Above
EMA 200
$187.79
Above
Fundamental Analysis
Valuation
68
Growth
55
Profitability
55
Financial Health
94
Cash Flow
70
Valuation
P/E Ratio
38.2×
P/B Ratio
1.70×
PEG Ratio
-0.83
Dividend Yield
0.00%
52W High
$222.15
52W Low
$131.52
Quality & Growth
ROE
708.4%
ROA
439.3%
Gross Margin
6770.7%
Operating Margin
1279.0%
Revenue Growth YoY
—
Debt / Equity
0.44
AI Fundamental Assessment
P/E ratio of 38.2 (rich relative to a 15-40x range); Price-to-book of 1.7x; PEG ratio of -0.8 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 7.1%; Return on assets of 4.4%; Net margin of 8.4%; Gross margin of 67.7%; Current ratio of 1.87 (healthy short-term liquidity); Debt-to-equity of 0.44; Free cash flow per share is positive (20.10); Most recent quarter beat estimates by 19.8%; 5 consecutive earnings beats; EPS growth decelerating (+79.4% -> +0.8% QoQ); Average YoY EPS growth of -34.2%; Analyst estimates rising over recent quarters
Get the Full BIIB Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →